Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 17 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

12%

2 trials in Phase 3/4

Results Transparency

13%

1 of 8 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2

5(38.5%)

N/A

3(23.1%)

Phase 1

3(23.1%)

Phase 3

1(7.7%)

Phase 4

1(7.7%)

13Total

Phase 2(5)

N/A(3)

Phase 1(3)

Phase 3(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (17)

Showing 17 of 17 trials

NCT03512249Phase 2Completed

Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence

Role: collaborator

NCT05122026Phase 1Active Not Recruiting

Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV

Role: lead

NCT05118490Phase 4Active Not Recruiting

Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients

Role: lead

NCT05122767Phase 1Active Not Recruiting

Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS)

Role: lead

NCT05686356Phase 2Active Not Recruiting

A Pan-TB Regimen Targeting Host and Microbe

Role: lead

NCT06909799Not ApplicableRecruiting

A Confirmatory Trial of Adjunctive NAC to Prevent Post Tuberculosis Lung Disease

Role: lead

NCT03702738Phase 2Completed

Adjunctive NAC in Adult Patients With Pulmonary Tuberculosis

Role: lead

NCT06511180Not Yet Recruiting

Introduction of Dispersible 3HP Formulations for TB Preventive Treatment in Children: a Multi-country Evaluation

Role: lead

NCT05515042Phase 2Active Not Recruiting

Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults.

Role: lead

NCT03435146Phase 1Completed

Safety Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine and Isoniazid or Standard Isoniazid Preventive Therapy in HIV+ Patients (DOLPHIN & DOLPHIN TOO)

Role: lead

NCT05643781Completed

Tuberculosis as a Risk Factor for a Worse Outcome Post-Sars-CoV-2 Infection

Role: lead

NCT03251196Unknown

TB Sequel: Pathogenesis and Risk Factors of Long-term Sequelae of Pulmonary TB

Role: lead

NCT02980016Phase 3Completed

Evaluation of the Effect of 3HP vs Periodic 3HP vs 6H in HIV-Positive Individuals

Role: lead

NCT02550067Not ApplicableCompleted

The Evidence for Contraceptive Options and HIV Outcomes Trial